3B Pharmaceuticals (3BP) and TetraKit Technologies (TT) have entered into a strategic partnership to co-develop next-generation targeted alpha therapies (TATs) for cancer. The collaboration combines 3BP’s expertise in precision oncology and radiopharmaceutical discovery with TT’s proprietary click chemistry-based radiolabeling platform, focusing on astatine-211.

Together, we aim to develop a novel peptide-based radioligand therapy designed to efficiently deliver astatine-211 to cancer cells. 3BP brings advanced drug discovery expertise and deep knowledge in precision oncology, while TetraKit Technologies provides its proprietary radiolabeling technology to enable reliable and efficient incorporation of radiohalogens. The goal is to advance a next-generation therapeutic that combines the strengths of both companies to address critical unmet needs in cancer care.